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Background
It has been postulated by Pascual and others that Anak-
inra works only early in systemic JIA (sJIA) and mainly on
systemic features. This paper specifically examines the
interval between the age of onset and time of starting Ana-
kinra for responders and non-responders, and considers
those with active systemic features versus persistent arthri-
tis and their response to Anakinra.
Methods
10 patients (3–17 yrs) with sJIA were enrolled onto a 12
week study at our institution. All patients fulfilled the
ILAR classification for sJIA. Out of the 10 patients, 9 had
failed anti-TNF. All patients received Anakinra at 2 mg/kg/
day subcutaneously with their current therapy, except
anti-TNF. Responders met Definition of Improvement
(DOI) criteria by >30% improvement in at least 3 of the
six JIA core set criteria with no more than 1 criteria wors-
ening by >30% as well as their serum SAA/CRP returning
to normal. Systemic features were documented.
Results
Of 10 subjects, 8 completed 12 weeks, 1 dropped out due
to lack of efficacy and 1 due to non-compliance. Duration
of JIA before starting Anakinra was 1–9 yrs, responders
have median duration of 2 yrs of JIA and non-responders
median duration of 6.5 yrs. The non-responders had no
systemic features at the start of Anakinra, whilst 3 out of 4
responders had fever at initiation of treatment and
improved in all.
Conclusion
Out of the 8 patients, the 4 responders started Anakinra a
median of two years into their sJIA. This group's persistent
systemic feature also improved. These findings support
the hypothesis by Pascual.
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